Previous studies have identified TIM3 (T-cell immunoglobulin domain and mucin domain 3) as a negative regulator of T helper 1 (T H 1)-cell responses. Now, new research shows that TIM3 is also ...

Novartis’ position as the frontrunner in the race to bring a Tim3-targeting drug to market has been lost after it pulled a phase 3 trial of its sabatolimab candidate. The STIMULUS-MDS2 trial was ...